|1.||Miyake, H: 1 article (12/2000)|
|2.||Sasaki, E: 1 article (12/2000)|
|3.||Nozawa, Y: 1 article (12/2000)|
|4.||Tanahashi, Y: 1 article (12/2000)|
|5.||Oda, N: 1 article (12/2000)|
|6.||Yamasaki, Y: 1 article (12/2000)|
|7.||Miyoshi, K: 1 article (12/2000)|
|8.||Terakawa, H: 1 article (12/2000)|
|9.||Matsuura, N: 1 article (12/2000)|
|10.||Muranaka, Y: 1 article (12/2000)|
|1.||Pathologic Constriction (Stenosis)
12/01/2000 - "The purpose of this study was to determine the efficacy and the possible mechanism of action of a recently synthesized drug, TAS-301 [3-bis(4-methoxyphenyl)methylene-2-indolinone], on stenosis after balloon overstretch injury of porcine arteries. "
12/01/2000 - "The oral administration of TAS-301 kept dilated the angiographic luminal diameter of injured segment 4 weeks after overstretch injury and reduced calculated stenosis ratio in a dose-dependent manner, significantly reducing it at doses of 30 and 100 mg/kg. Histopathological analysis showed that TAS-301 significantly reduced the adventitial area at doses of 30 and 100 mg/kg with moderate reduction of the neointimal area, resulting in the larger residual lumen. "
|2.||Coronary Stenosis (Coronary Artery Stenosis)
12/01/2000 - "These findings indicate that TAS-301, the first compound developed for targeting the constrictive remodeling, showed a high inhibitory potency on coronary artery stenosis of micropigs after injury, mainly due to inhibition of adventitial fibroblast proliferation and of the contractile ability of myofibroblasts. "